Simcere Pharmaceutical Group Limited

OTCPK:SMHG.F Stock Report

Market Cap: US$1.8b

Simcere Pharmaceutical Group Past Earnings Performance

Past criteria checks 1/6

Simcere Pharmaceutical Group has been growing earnings at an average annual rate of 20.5%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 10.4% per year. Simcere Pharmaceutical Group's return on equity is 9.9%, and it has net margins of 10.8%.

Key information

20.5%

Earnings growth rate

17.7%

EPS growth rate

Pharmaceuticals Industry Growth6.0%
Revenue growth rate10.4%
Return on equity9.9%
Net Margin10.8%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Simcere Pharmaceutical Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OTCPK:SMHG.F Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 236,6087152,8551,563
30 Sep 236,8061,9282,9971,708
30 Jun 236,9993,1443,1381,853
31 Mar 236,6592,0382,9851,790
31 Dec 226,3249312,8351,728
30 Sep 225,9529722,7091,585
30 Jun 225,5791,0132,5841,441
31 Mar 225,2901,2602,5011,429
31 Dec 215,0001,5072,4191,417
30 Sep 214,8521,2742,3061,366
30 Jun 214,7031,0422,1931,315
31 Mar 214,6068562,0881,228
31 Dec 204,5096701,9821,142
30 Sep 204,5286991,9901,030
30 Jun 204,5487281,997918
31 Mar 204,7928662,183817
31 Dec 195,0371,0042,368716
31 Dec 184,5147342,512447
31 Dec 173,8683502,433212
30 Sep 132,0271931,328200
30 Jun 132,111421,413217

Quality Earnings: SMHG.F has a high level of non-cash earnings.

Growing Profit Margin: SMHG.F's current net profit margins (10.8%) are lower than last year (14.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: SMHG.F's earnings have grown significantly by 20.5% per year over the past 5 years.

Accelerating Growth: SMHG.F's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.

Earnings vs Industry: SMHG.F had negative earnings growth (-23.2%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-13.2%).


Return on Equity

High ROE: SMHG.F's Return on Equity (9.9%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies